280 related articles for article (PubMed ID: 17043436)
61. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
62. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
63. Developing of granulomatous thyroiditis during etanercept therapy.
Cañas CA; Tobón GJ; Arango LG; Guarín N
Clin Rheumatol; 2009 Jun; 28 Suppl 1():S17-9. PubMed ID: 19043773
[TBL] [Abstract][Full Text] [Related]
64. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
65. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
66. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
67. Systemic sarcoidosis induced by etanercept: first Brazilian case report.
Unterstell N; Bressan AL; Serpa LA; Fonseca e Castro PP; Gripp AC
An Bras Dermatol; 2013; 88(6 Suppl 1):197-9. PubMed ID: 24346918
[TBL] [Abstract][Full Text] [Related]
68. [Minimal change nephrotic syndrome developing in a rheumatoid arthritis patient under etanercept treatment].
Takeuchi T; Takegawa M; Ito Y; Kishi F; Miyamoto M; Minakata T
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Jun; 31(3):178-82. PubMed ID: 18587229
[TBL] [Abstract][Full Text] [Related]
69. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.
Haraoui B; Keystone E
Curr Opin Rheumatol; 2006 Jan; 18(1):96-100. PubMed ID: 16344625
[TBL] [Abstract][Full Text] [Related]
70. Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept.
Allanore Y; Brémont C; Kahan A; Menkès CJ
Clin Exp Rheumatol; 2001; 19(3):356-7. PubMed ID: 11407100
[No Abstract] [Full Text] [Related]
71. Development of recurrent pseudoseptic arthritis in a patient with rheumatoid arthritis receiving TNF-alpha blocker.
Korkmaz C; Kaşifoğlu T
Joint Bone Spine; 2006 Dec; 73(6):767-8. PubMed ID: 17126056
[No Abstract] [Full Text] [Related]
72. Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis.
Tack CJ; Kleijwegt FS; Van Riel PL; Roep BO
Diabetologia; 2009 Jul; 52(7):1442-4. PubMed ID: 19440690
[No Abstract] [Full Text] [Related]
73. Successful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy.
Szalay B; Acs L; Vásárhelyi B; Kovács L; Balog A
J Clin Rheumatol; 2011 Oct; 17(7):377-9. PubMed ID: 21946465
[TBL] [Abstract][Full Text] [Related]
74. Development of sarcoidosis during etanercept therapy.
Ishiguro T; Takayanagi N; Kurashima K; Matsushita A; Harasawa K; Yoneda K; Tsuchiya N; Miyahara Y; Yamaguchi S; Yano R; Tokunaga D; Saito H; Ubukata M; Yanagisawa T; Sugita Y; Kawabata Y
Intern Med; 2008; 47(11):1021-5. PubMed ID: 18520114
[TBL] [Abstract][Full Text] [Related]
75. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis.
Doulton TW; Tucker B; Reardon J; Velasco N
Clin Nephrol; 2004 Sep; 62(3):234-8. PubMed ID: 15481857
[TBL] [Abstract][Full Text] [Related]
76. Viral pneumonia as a serious complication of etanercept therapy.
Smith D; Letendre S
Ann Intern Med; 2002 Jan; 136(2):174. PubMed ID: 11790076
[No Abstract] [Full Text] [Related]
77. TNF-alpha antagonist induced lupus on three different agents.
Mudduluru BM; Shah S; Shamah S; Swaminath A
Postgrad Med; 2017 Mar; 129(2):304-306. PubMed ID: 27748629
[TBL] [Abstract][Full Text] [Related]
78. Foot ulcers caused by rheumatoid vasculitis in a patient with rheumatoid arthritis undergoing etanercept treatment.
Murosaki T; Nagashima T; Aoki Y; Imai Y; Iwamoto M; Minota S
Intern Med; 2012; 51(22):3181-3. PubMed ID: 23154729
[TBL] [Abstract][Full Text] [Related]
79. Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease.
Richez C; Blanco P; Dumoulin C; Schaeverbeke T
Clin Exp Rheumatol; 2005; 23(2):273. PubMed ID: 15895904
[No Abstract] [Full Text] [Related]
80. [Onset of modified measles after etanercept treatment in rheumatoid arthritis].
Takahashi E; Kurosaka D; Yoshida K; Yanagimachi M; Kingetsu I; Yamada A
Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(1):37-41. PubMed ID: 20190509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
